Clinical Trials

Date of Origin: 01/2009  Last Review Date: 07/24/2019  Effective Date: 08/01/2019


Developed By: Medical Necessity Criteria Committee

I. Description

Clinical trials are research studies designed to evaluate the safety and effectiveness of new medical treatments, drugs, diagnostic tests, and screenings. They are scientific investigations that compare new, untested, or non-standard treatment to standard treatments that are currently accepted and utilized in the medical community. All clinical trials are based on a set of rules called a protocol. The protocol describes all study details including characteristics of people who may or may not participate, the length of the study, schedule of tests, procedures, medications, etc. Clinical trials generally consist of the following four phases.

**Phase I:** Researcher tests a new drug or treatment in a small group of people for the first time to evaluate safety, determine a safe dosage range, and identify side effects.

**Phase II:** The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

**Phase III:** The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

**Phase IV:** Studies are performed after the drug or treatment has been marketed to gather information about its effect in various populations and any side effects associated with long-term use.

There are two types of costs associated with a clinical trial: patient care costs and research costs.

**Patient care costs** fall into two categories:
- Usual care costs, such as doctor visits, hospital stays, clinical laboratory tests, x-rays, etc. which occur whether the patient is participating in a trial or receiving standard treatment. These costs are usually covered by a third-party health plan.

- Extra care costs associated with clinical trial participation, such as the additional tests that may or may not be fully covered by the clinical trial sponsor and/or research institution.
**Research costs** are those associated with conducting the clinical trial, such as data collection and management, research physician and nurse time, analysis of results and tests purely performed for research purposes. Such costs are usually covered by the organization sponsoring the clinical trial. Costs for the drugs or devices being studied may also be covered by the organization sponsoring the clinical trial.

II. Criteria: CWQI HCS-0017

A. Moda Health will cover the following Clinical Trials that are considered qualified when **1 or more** of the following are met:

   a. **Qualified clinical trial for Oregon members** are limited to trials meeting **All** of the following:
      i. Funded, or supported by a center of cooperative group that is funded by **1 or more** of the following:
         1. National Institutes of Health
         2. Centers for Disease Control and Prevention
         3. Agency for Healthcare Research and Quality
         4. Centers for Medicare and Medicaid Services
         5. United States Department of Defense
         6. United States Department of Veterans Affairs
      ii. The clinical trial meets **1 or more** of the following:
         1. Conducted as **1 or more** of the following:
            a. An investigational new drug application
            b. An investigational device exemption
            c. A biologics license application to the United States Food and Drug Administration
         2. Exempt by federal law from the requirement to submit an investigational new drug application to the United States Food and Drug Administration

   b. **Qualified clinical trials for Alaska members** are limited to trials that meet **All** of the following:
      i. An approved clinical trial includes **1 or more** of the following:
         1. A scientific study using human subjects designed to test and improve prevention, diagnosis, treatment or palliative care of cancer; or
         2. The safety and effectiveness of a drug, device, or procedure used in the prevention, diagnosis, treatment or palliative care of a subject.
      ii. The study must be approved by **All** of the following:
         1. An institutional review board that complies with 45 CFR Part 46 and **1 or more** of the following:
            a. United States Department of Health and Human Services, National Institute of Health, or its institutes or centers
            b. United States Department of Health and Human Services, United States Food and Drug Administration
            c. United States Department of Defense
            d. United States Department of Veterans Affairs.
e. A non-governmental research entity abiding by current National Institutes of Health guidelines.

B. If the above criteria are not met, the study is not considered a qualified clinical trial. Please refer to the Moda Health Experimental and Investigational Services and Supplies Criteria.

C. Moda Health will cover Patient Care Costs in Clinical Trials that meet 1 or more of the following:

a. Oregon Members
   i. Moda Health will cover routine costs in clinical trials for Oregon members and ALL of the following:
      1. Routine cases for the care of a member who is enrolled in or participating in a qualifying clinical trial are covered as defined by ALL of the following:
         a. Routine costs mean medically necessary conventional care, items or services covered by the healthcare insurance plan if typically provided absent a clinical trial (i.e. hospital costs, labs, imaging)
      2. Limitations as indicated by ALL of the following:
         a. Routine costs will be subject to the applicable cost sharing as if provided in the absence of a clinical trial.
         b. Routine costs for treatment of adverse effects of a clinical trial are covered.
   ii. All of the following services are Not Covered by Moda Health
      1. The drug, device or service being tested in the clinical trial unless it would be covered by the Moda Health plan if provided outside of a clinical trial.
      2. Items or services required solely for the provision of the drug, device, or service being tested in the clinical trial.
      3. Items or services required solely for the clinically appropriate monitoring of the drug, device, or services being tested in the clinical trial.
      4. Items or services that are provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management of the member
      5. Items or services customarily provided by a clinical trial sponsor free of charge to any person participating in the clinical trial; or
      6. Items or services that are not covered by Moda Health if provided outside of the clinical trial.

b. Alaska Members:
   i. Moda Health will cover routine costs for the care of an Alaska member who is enrolled in an approved clinical trial as defined in federal or state laws related to cancer or other life-threatening disease or condition, including leukemia, lymphoma and bone marrow stem cell disorders and meets ALL of the following:
      1. Only if the member’s treating physicians determines that there is no clear superior non-investigational treatment alternative; and
2. Available clinical or preclinical data provide a reasonable expectation that the treatment provided in the clinical trial will be at least as efficacious as any non-investigational alternative.

ii. Limitations as indicated by ALL of the following:
   1. Covered costs will be subject to applicable cost sharing as if provided in absence of a clinical trial
   2. Routine costs for treatment of adverse effects of a clinical trial are covered.

iii. **All of the following** costs are covered in addition to the standard routine costs.
   1. Prevention, diagnosis, treatment, and palliative care of a qualified medical condition.
   2. Medical care for an approved clinical trial that would otherwise be covered under a health benefit plan if the medical care were not in connection with an approved clinical trial related to a qualified medical condition.
   3. Items or services necessary to provide an investigational item or service
   4. The diagnosis or treatment of complications
   5. A drug or device approved by the United States Food and Drug administration (FDA) without regard to whether the FDA approved the drug or device for use in treating a member’s particular condition, but only to the extent that the drug or device is not paid for by the manufacturer, distributor, or provider of the drug or device.
   6. Services necessary to administer a drug or device under evaluation in the clinical trial
   7. Transportation for the member that is primarily for and essential to the medical case

iv. **Not covered as indicated by ALL of the following:**
   1. A drug or device that is associated with the clinical trial that has not been approved by the FDA
   2. Housing, companion expenses, or other non-clinical expenses associated with the clinical trial.
   3. An item or service provided solely to satisfy data collection and analysis and not used in the clinical management of the member
   4. An item or service excluded from coverage in the **General Exclusions** section of the member handbook
   5. An item or service paid for or customarily paid for through grants or other funding

D. **Federal Regulations for Clinical Trials- General Regulations governing all States.**

   **Qualified clinical trials**
   a. An approved clinical trial means a phase I, phase II, phase III, or phase IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-threatening disease or condition and is described in any of the following subparagraphs:
i. The study or investigation is approved or funded by **1 or more** of the following:
   1. The National Institutes of Health
   2. The Centers for Disease Control and Prevention
   3. The Agency for Health Care Research and Quality
   4. The Centers for Medicare & Medicaid Services
   5. Cooperative group or center of any of the entities described in 1-4 or the Department of Defense or the Department of Veterans Affairs.
   6. A qualified non-governmental research entity identified in the guidelines issued by the National Institutes of Health for center support grants.
   7. Any of the following if the conditions described in paragraph II.D.b are met:
      a. The Department of Veterans Affairs
      b. The Department of Defense
      c. The Department of Energy

ii. The study or investigation is conducted under an investigational new drug application reviewed by the Food and Drug Administration

iii. The study or investigation is a drug trial that is exempt from having such an investigational new drug application

b. The conditions described in this paragraph, for a study or investigation conducted by a Department, are that the study or investigation has been reviewed and approved through a system of peer review that the Secretary determines
   i. To be comparable to the system of peer review of studies and investigations used by the National Institutes of Health, and
   ii. Assures unbiased review of the highest scientific standards by qualified individuals who have no interest in the outcome of the review.

c. **Criteria for Coverage of Patient Care Costs in Clinical Trials:**
   i. The individual is eligible to participate in an approved clinical trial according to the trial protocol with respect to treatment of cancer or other life-threatening disease or condition
   ii. And **1 or more** of the following:
      1. The referring health care professional is a participating health care provider and has concluded that the individual’s participation in such trial would be appropriate based upon the individual meeting the conditions described in paragraph (i); or
      2. The participant or beneficiary provides medical and scientific information establishing that the individual’s participation in such trial would be appropriate based on the individual meeting the conditions described in paragraph (i).

d. **Not covered:**
   i. The investigation item, device, or service, itself
   ii. Items and services that are provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management of the patient, or
   iii. A service that is clearly inconsistent with widely accepted and established standards of care for a particular diagnosis.
III. Information Submitted with the Prior Authorization Request:
1. History and physical
2. Treatment history for the condition for which a clinical trial is being requested
3. A detailed clinical trial protocol
4. A copy of the informed-consent document signed by the patient
5. A copy of the Institutional Review Board (IRB) approval

IV. CPT or HCPC codes covered:

<table>
<thead>
<tr>
<th>Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G0293</td>
<td>Noncovered surgical procedure(s) using conscious sedation, regional, general or spinal anesthesia in a Medicare qualifying clinical trial, per day</td>
</tr>
<tr>
<td>G0294</td>
<td>Noncovered surgical procedure(s) using either no anesthesia or local anesthesia only, in a Medicare qualifying clinical trial, per day</td>
</tr>
<tr>
<td>S9988</td>
<td>Services provided as a part of a phase I clinical trial</td>
</tr>
<tr>
<td>S9990</td>
<td>Services provided as a part of a phase II clinical trial</td>
</tr>
<tr>
<td>S9991</td>
<td>Services provided as a part of a phase III clinical trial</td>
</tr>
<tr>
<td>S9992</td>
<td>Transportation costs to and from trial location and local transportation costs (e.g., fares for taxicab or bus) for clinical trial participant and one caregiver/companion</td>
</tr>
<tr>
<td>S9994</td>
<td>Lodging costs (e.g., hotel charges) for clinical trial participant and one caregiver/companion</td>
</tr>
<tr>
<td>S9996</td>
<td>Meals for clinical trial participant and one caregiver/companion</td>
</tr>
<tr>
<td>Modifier Q0</td>
<td>Investigational clinical service provided in a clinical research study that is in an approved clinical research study</td>
</tr>
<tr>
<td>Modifier Q1</td>
<td>Routine clinical service provided in a clinical research study that is in an approved clinical research study</td>
</tr>
</tbody>
</table>

V. Annual Review History

<table>
<thead>
<tr>
<th>Review Date</th>
<th>Revisions</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/2009</td>
<td>Criteria Developed</td>
<td>01/2009</td>
</tr>
<tr>
<td>02/2011</td>
<td>Annual Review</td>
<td>02/2011</td>
</tr>
<tr>
<td>09/2012</td>
<td>Annual Review: - Added Alaska Regulations</td>
<td>09/26/2012</td>
</tr>
<tr>
<td>07/2013</td>
<td>Annual Review</td>
<td>07/2013</td>
</tr>
<tr>
<td>07/2014</td>
<td>Annual Review</td>
<td>07/2014</td>
</tr>
<tr>
<td>06/2015</td>
<td>Annual Review- included Medicare criteria, added California regulations</td>
<td>06/15</td>
</tr>
<tr>
<td>05/2016</td>
<td>Annual Review: Removed CA regulations. Updated wording added by Regulatory</td>
<td>06/16</td>
</tr>
<tr>
<td>05/2017</td>
<td>Annual Review: Updated to new template</td>
<td>05/24/2017</td>
</tr>
</tbody>
</table>
Appendix 1 – Covered Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD 10 code</th>
<th>ICD 10 Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z00.6</td>
<td>Encounter for examination for normal comparison and control in clinical research program</td>
</tr>
</tbody>
</table>

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.
Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

<table>
<thead>
<tr>
<th>Jurisdiction(s): 5, 8</th>
<th>NCD/LCD Document(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CMS National Coverage Determination (NCD) for Routine Costs in CLINICAL TRIALS (310.1)</td>
</tr>
</tbody>
</table>

**Medicare Part B Administrative Contractor (MAC) Jurisdictions**

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
</tbody>
</table>